Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
Latest Information Update: 30 Jun 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Autoimmune disorders; Psoriasis
- Focus Pharmacokinetics
- Sponsors BioRay Pharmaceutical
Most Recent Events
- 24 Jun 2025 Status changed from not yet recruiting to completed.
- 17 Nov 2023 New trial record